JP5596680B2 - 経口抗がん製剤 - Google Patents
経口抗がん製剤 Download PDFInfo
- Publication number
- JP5596680B2 JP5596680B2 JP2011517646A JP2011517646A JP5596680B2 JP 5596680 B2 JP5596680 B2 JP 5596680B2 JP 2011517646 A JP2011517646 A JP 2011517646A JP 2011517646 A JP2011517646 A JP 2011517646A JP 5596680 B2 JP5596680 B2 JP 5596680B2
- Authority
- JP
- Japan
- Prior art keywords
- formulation
- weight
- transcutol
- tpgs
- peg
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/171,515 | 2008-07-11 | ||
US12/171,515 US8026271B2 (en) | 2008-07-11 | 2008-07-11 | Formulations of indol-3-yl-2-oxoacetamide compounds |
PCT/US2009/050210 WO2010006234A2 (en) | 2008-07-11 | 2009-07-10 | Anticancer oral formulation |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2011527704A JP2011527704A (ja) | 2011-11-04 |
JP2011527704A5 JP2011527704A5 (zh) | 2012-08-16 |
JP5596680B2 true JP5596680B2 (ja) | 2014-09-24 |
Family
ID=41505721
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011517646A Expired - Fee Related JP5596680B2 (ja) | 2008-07-11 | 2009-07-10 | 経口抗がん製剤 |
Country Status (8)
Country | Link |
---|---|
US (1) | US8026271B2 (zh) |
EP (1) | EP2310363B1 (zh) |
JP (1) | JP5596680B2 (zh) |
KR (1) | KR101627382B1 (zh) |
CN (1) | CN102159541B (zh) |
ES (1) | ES2426599T3 (zh) |
TW (1) | TWI384984B (zh) |
WO (1) | WO2010006234A2 (zh) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8026271B2 (en) * | 2008-07-11 | 2011-09-27 | National Health Research Institutes | Formulations of indol-3-yl-2-oxoacetamide compounds |
CN104945420A (zh) | 2009-06-29 | 2015-09-30 | 因塞特公司 | 作为pi3k抑制剂的嘧啶酮类 |
US8759359B2 (en) * | 2009-12-18 | 2014-06-24 | Incyte Corporation | Substituted heteroaryl fused derivatives as PI3K inhibitors |
TW201130842A (en) * | 2009-12-18 | 2011-09-16 | Incyte Corp | Substituted fused aryl and heteroaryl derivatives as PI3K inhibitors |
JP5816678B2 (ja) | 2010-04-14 | 2015-11-18 | インサイト・コーポレイションIncyte Corporation | PI3Kδ阻害剤としての縮合誘導体 |
US9062055B2 (en) | 2010-06-21 | 2015-06-23 | Incyte Corporation | Fused pyrrole derivatives as PI3K inhibitors |
AR084366A1 (es) | 2010-12-20 | 2013-05-08 | Incyte Corp | N-(1-(fenil sustituido)etil)-9h-purin-6-aminas como inhibidores de pi3k |
WO2012125629A1 (en) | 2011-03-14 | 2012-09-20 | Incyte Corporation | Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors |
WO2012135009A1 (en) | 2011-03-25 | 2012-10-04 | Incyte Corporation | Pyrimidine-4,6-diamine derivatives as pi3k inhibitors |
TR201906779T4 (tr) | 2011-05-12 | 2019-05-21 | Proteostasis Therapeutics Inc | Proteostaz regülatörleri. |
HUE043703T2 (hu) | 2011-09-02 | 2019-09-30 | Incyte Holdings Corp | Heterociklusos aminok PI3K inhibitorokként |
AR090548A1 (es) | 2012-04-02 | 2014-11-19 | Incyte Corp | Azaheterociclobencilaminas biciclicas como inhibidores de pi3k |
WO2015073528A1 (en) | 2013-11-12 | 2015-05-21 | Proteostasis Therapeutics, Inc. | Proteasome activity enhancing compounds |
US10077277B2 (en) | 2014-06-11 | 2018-09-18 | Incyte Corporation | Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors |
TWI764392B (zh) | 2015-02-27 | 2022-05-11 | 美商英塞特公司 | Pi3k抑制劑之鹽及製備方法 |
WO2016183063A1 (en) | 2015-05-11 | 2016-11-17 | Incyte Corporation | Crystalline forms of a pi3k inhibitor |
US9732097B2 (en) | 2015-05-11 | 2017-08-15 | Incyte Corporation | Process for the synthesis of a phosphoinositide 3-kinase inhibitor |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6979456B1 (en) | 1998-04-01 | 2005-12-27 | Jagotec Ag | Anticancer compositions |
US6372251B2 (en) | 1999-06-11 | 2002-04-16 | Abbott Laboratories | Formulations comprising lipid-regulating agents |
US20040092428A1 (en) * | 2001-11-27 | 2004-05-13 | Hongming Chen | Oral pharmaceuticals formulation comprising paclitaxel, derivatives and methods of administration thereof |
US6903104B2 (en) | 2001-12-06 | 2005-06-07 | National Health Research Institutes | Indol-3-YL-2-oxoacetamide compounds and methods of use thereof |
RU2007123366A (ru) * | 2004-11-24 | 2008-12-27 | Мерк Энд Ко. | Жидкие и полутвердые фармацевтические препаративные формы для перорального введения замещенного амида |
US20060134204A1 (en) * | 2004-12-21 | 2006-06-22 | Wong Patrick S | Complexes made using low solubility drugs |
TWI376239B (en) | 2006-02-01 | 2012-11-11 | Andrew Xian Chen | Vitamin e succinate stabilized pharmaceutical compositions, methods for the preparation and the use thereof |
BRPI0717721A2 (pt) * | 2006-11-28 | 2013-10-29 | Marinus Pharmaceuticals | "partículas complexadas de drogas, composição farmacêutica, uso de uma composição farmacêutica, partículas complexadas de droga estabilizadas no tamanho, método para a preparação de partículas estabilizadas da droga, composição farmacêutica sólida, comprimido oral ingerível e composição líquida em nanopartículas estabilizadas no tamanho" |
JP2010516626A (ja) * | 2007-01-16 | 2010-05-20 | バイパー サイエンシズ,インコーポレイティド | ガン治療剤 |
US8026271B2 (en) | 2008-07-11 | 2011-09-27 | National Health Research Institutes | Formulations of indol-3-yl-2-oxoacetamide compounds |
-
2008
- 2008-07-11 US US12/171,515 patent/US8026271B2/en not_active Expired - Fee Related
-
2009
- 2009-07-09 TW TW098123197A patent/TWI384984B/zh not_active IP Right Cessation
- 2009-07-10 EP EP09795224.6A patent/EP2310363B1/en not_active Not-in-force
- 2009-07-10 JP JP2011517646A patent/JP5596680B2/ja not_active Expired - Fee Related
- 2009-07-10 WO PCT/US2009/050210 patent/WO2010006234A2/en active Application Filing
- 2009-07-10 CN CN200980126979.4A patent/CN102159541B/zh not_active Expired - Fee Related
- 2009-07-10 ES ES09795224T patent/ES2426599T3/es active Active
- 2009-07-10 KR KR1020117003208A patent/KR101627382B1/ko not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
US20100010059A1 (en) | 2010-01-14 |
EP2310363A4 (en) | 2012-03-28 |
WO2010006234A3 (en) | 2010-04-08 |
ES2426599T3 (es) | 2013-10-24 |
TWI384984B (zh) | 2013-02-11 |
US8026271B2 (en) | 2011-09-27 |
WO2010006234A2 (en) | 2010-01-14 |
CN102159541B (zh) | 2014-06-04 |
CN102159541A (zh) | 2011-08-17 |
KR101627382B1 (ko) | 2016-06-03 |
TW201002319A (en) | 2010-01-16 |
EP2310363A2 (en) | 2011-04-20 |
EP2310363B1 (en) | 2013-06-05 |
KR20110038135A (ko) | 2011-04-13 |
JP2011527704A (ja) | 2011-11-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5596680B2 (ja) | 経口抗がん製剤 | |
JP3087763B2 (ja) | 新規な複素環式化合物およびそれを含有する医薬組成物 | |
JP6087367B2 (ja) | 三環式化合物、それらを含む組成物およびそれらの使用 | |
CN107635979A (zh) | 溴结构域抑制剂 | |
CN106478502B (zh) | 1,2,3,4-四氢异喹啉衍生物、其制备方法和应用 | |
JP6174627B2 (ja) | (+)−1,4−ジヒドロ−7−[(3s,4s)−3−メトキシ−4−(メチルアミノ)−1−ピロリジニル]−4−オキソ−1−(2−チアゾリル)−1,8−ナフチリジン−3−カルボン酸の製造方法 | |
JP6742343B2 (ja) | 2環性複素環化合物 | |
CN111150731A (zh) | 含氧吡格雷光学异构体或其盐的组合物及应用 | |
WO2019042443A1 (zh) | 一类具有降解酪氨酸蛋白激酶jak3活性的化合物 | |
BR112016009918B1 (pt) | Composto apresentando maior inibição da atividade da proteína quinase g, seu uso e seu método de preparação, e composição farmacêutica | |
WO2019001307A1 (zh) | 一种酰胺类化合物及包含该化合物的组合物及其用途 | |
JP2019089822A (ja) | トピロキソスタットの新規結晶形及びその製造方法 | |
KR20200099016A (ko) | 모사프리드시트르산염수화물의 제조방법 및 이를 포함하는 약학제제 | |
JP7134983B2 (ja) | テトラヒドロナフチルウレア誘導体の結晶 | |
CN109988199B (zh) | 红景天苷衍生物及其用途 | |
CN107304188A (zh) | 一种氘代激酶选择性抑制剂及其应用 | |
JP2002527442A (ja) | 心血管、抗腫瘍、抗感染症、および抗炎症の活性を有するイミダゾ−ベンゾアゼピン | |
JPH11514383A (ja) | 神経保護活性を有するチアモルヒナン | |
KR20050084815A (ko) | 의약 조성물 | |
JPH07506844A (ja) | 硝酸1,2‐ベンゾ‐イソチアゾリル‐3(2h)オン‐1,1‐ジオキシドエステル,それらの製造法及びそれらを含む薬 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120702 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20120702 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20131029 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140114 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140121 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140226 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20140715 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20140807 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5596680 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |